Hong Zhang

A multifunctional tripodal fluorescent probe for the recognition of Cr3+, Al3+, Zn2+ and F− with controllable ESIPT processes

Zongwen Jin, L. Mu, C. Redshaw, 2019, Dyes and Pigments.

Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study

Yongmei Yin, Bing-he Xu, Huiping Li, 2020, Breast Cancer Research and Treatment.

Favezelimab (anti–LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti–PD-1 treatment: An open-label phase 1/2 study.

N. Johnson, P. Zinzani, A. Bazargan, 2022, Journal of Clinical Oncology.

A phase III, randomized, double-blind, placebo (Pla)-controlled study of pertuzumab (P) + trastuzumab (H) + docetaxel (D) versus Pla + H+ D in previously untreated HER2-positive locally recurrent/metastatic breast cancer (LR/MBC) (PUFFIN).

Yongmei Yin, Bing-he Xu, Huiping Li, 2019, Journal of Clinical Oncology.